Država: Kanada
Jezik: engleski
Izvor: Health Canada
ZOLEDRONIC ACID (ZOLEDRONIC ACID MONOHYDRATE)
NOVARTIS PHARMACEUTICALS CANADA INC
M05BA08
ZOLEDRONIC ACID
4MG
POWDER FOR SOLUTION
ZOLEDRONIC ACID (ZOLEDRONIC ACID MONOHYDRATE) 4MG
INTRAVENOUS
6ML
Prescription
BONE RESORPTION INHIBITORS
Active ingredient group (AIG) number: 0141761001; AHFS:
CANCELLED POST MARKET
2008-10-31
_ _ _Page 1 of _47 PRODUCT MONOGRAPH Pr ZOMETA* Lyophilized Powder (Zoledronic acid for Injection) 4 mg/vial Pr ZOMETA* Concentrate (Zoledronic acid for Injection) 4 mg zoledronic acid/5 mL incorporated as the monohydrate Bone Metabolism Regulator Novartis Pharmaceuticals Canada Inc. Dorval, Quebec H9S 1A9 Date of Preparation: August 16, 2000 Date of Revision: September 20, 2005 CONTROL # 097402 Pr ZOMETA* is a registered trademark _ _ _Page 2 of _47 Table of Contents PART I: HEALTH PROFESSIONAL INFORMATION.........................................................3 SUMMARY PRODUCT INFORMATION ........................................................................3 INDICATIONS AND CLINICAL USE..............................................................................3 CONTRAINDICATIONS ...................................................................................................4 WARNINGS AND PRECAUTIONS..................................................................................4 ADVERSE REACTIONS....................................................................................................9 DRUG INTERACTIONS ....................................................................................................5 DOSAGE AND ADMINISTRATION..............................................................................17 OVERDOSAGE ................................................................................................................21 ACTION AND CLINICAL PHARMACOLOGY ............................................................21 STORAGE AND STABILITY..........................................................................................25 DOSAGE FORMS, COMPOSITION AND PACKAGING .............................................25 PART II: SCIENTIFIC INFORMATION ...............................................................................27 PHARMACEUTICAL INFORMATION..........................................................................27 CLINICAL TRIALS....................................... Pročitajte cijeli dokument